c/o JLABS, 329 Oyster Point Blvd, 3rd Floor
South San Francisco
6 articles with CODA Biotherapeutics
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
CODA Biotherapeutics Receives Grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to Help Advance its Next-Generation Gene Therapy-Mediated Chemogenetic Platform
NINDS Small Business Innovation Research grant of $670K over two years to support CODA's neuropathic pain program Company also selected for collaboration with NIH's National Center for Advancing Translational Science
Strategic partnership supports CODA's efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain [20-May-2020] SOUTH SAN FRANCISCO, Calif. , May 20, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today annou
CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of Attenua, Inc.
CODA Biotherapeutics Deepens Gene Therapy Expertise with Industry Veteran, Annahita Keravala, Ph.D., and Key Promotions
Expansion and development of leadership team drives the company's chemogenetic gene therapy platform toward the clinic in initial core therapeutic areas of chronic neuropathic pain and focal epilepsy
Proceeds will advance company's chemogenetic gene therapy platform toward the clinic with an initial focus on chronic neuropathic pain and focal epilepsy